Document is current
Any future updates will be listed below
-
Authors
Button, Elise https://orcid.org/0009-0000-9534-5420
Carter, Hannah
Gavin, Nicole C.
LeBlanc, Thomas W.
McCaffrey, Nikki
-
Funding
Funding for this research was provided by:
Queensland University of Technology
- License Information
-
More Information
Article History
Accepted: 7 July 2024
First Online: 22 August 2024
Declarations
:
: Elise Button, Nikki McCaffrey, Hannah Carter, and Nicole Gavin declare they have no financial interests. Thomas LeBlanc has the following declarations: (i) currently, or has recently been a consultant for/received honoraria from AbbVie, Agilix, Agios/Servier, Astellas, AstraZeneca, Beigene, BlueNote, BMS/Celgene, CareVive, Flatiron, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer; (ii) served on recent advisory boards for AbbVie, Agios, and BMS; ii) has received honoraria from AbbVie, Agios, Astellas, BMS/Celgene, and Incyte for recent speaking engagements; iv) has equity interest in Dosentrx; v) and has received recent research funding from the AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society, the National Institute of Nursing Research/ National Institutes of Health, and Seattle Genetics.
